Indeed, the phase III trial investigation by French Intergroup (IFCT) showed the predictive values of RASSF1A methylation pattern, for predicting survival following neoadjuvant chemotherapy in patients with stage I–II NSCLC: a poor median overall survival was observed in patients with methylated RASSF1 promoter treated with gemcitabine (30.3 months) compared with those treated with paclitaxel (70 months)11. This evidence concerns the gene RASSF1 and non-small cell lung carcinoma.